Browse Studies — Arctuva

Phase 1

TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer

The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with d…

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07190300

Phase 2

A Phase II Randomized Trial of Intermittent Androgen Deprivation Therapy Alone or Combined With [177Lu]Lu-PSMA-617, With or Without Abiraterone and Prednisone, in Patients With Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treat…

Recurrent Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8Castration-Sensitive Prostate Cancer+9 more

Estimated

~$10 – $6,250

Mayo ClinicNCT07650240

Phase 1

A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Estimated

~$10 – $7,500

AmgenNCT07140900

Phase 2

A Phase II Randomized, Decentralized, De-escalation Study in Patients With Metastatic Hormone-Sensitive Prostate Cancer Achieving Optimal PSA Response (OPTIMAS)

The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive pros…

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Estimated

~$10 – $6,250

University of UtahNCT07216248

Phase 2

A Pragmatic Phase 2 Trial of Risk-Adapted Treatment Approaches Including Treatment De-escalation to Minimize Adverse Effects of Hormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

This is a prospective, interventional, non-randomized, phase 2 study to assess oncologic outcomes of metastatic hormone-sensitive prostate cancer (mCSPC) patie…

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Estimated

~$10 – $6,250

Georgetown UniversityNCT07645326